Sorafenib improves the postoperative effect of early stage renal cell carcinoma

Liu,Taiyang; Li,Jie; Wen,Xiuhua; Hui,Zhang; Qi,Gui

doi:10.3892/ol.2016.5243

Sorafenib improves the postoperative effect of early stage renal cell carcinoma

Authors:
- Taiyang Liu
- Jie Li
- Xiuhua Wen
- Zhang Hui
- Gui Qi
View Affiliations

Affiliations: Department of Urology, Zhumadian Central Hospital, Zhumadian, Henan 463000, P.R. China
Published online on: October 12, 2016 https://doi.org/10.3892/ol.2016.5243
Pages: 4367-4370
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sorafenib was examined to determine whether it improves postoperative effects during early stage renal cell carcinoma (RCC). A total of 133 patients with early renal clear cell carcinoma (T1‑2N0M0) with surgical indications were continuously selected. The patients were divided into 3 groups according to different treatments, including the surgery alone group (40 cases), surgery combined with cytokine group (45 cases) and surgery combined with sorafenib group (48 cases), to make a comparison of their clinical effects. The surgery combined with sorafenib group significantly reduced the recurrence rate and increased the survival rate (P<0.05). Its median survival period was >30 months and the other 2 groups were 27 months (P<0.05). In the subsequent 3 months patients were followed up and it was found that the creatinine levels were significantly elevated and hemoglobin levels were significantly decreased. The sorafenib group had significantly lower creatinine levels and higher hemoglobin levels than the other 2 groups (P<0.05). In the 3‑month follow-up, vascular endothelial growth factor (VEGF) levels were significantly reduced and tumor necrosis factor (TNF)‑α levels were elevated, although the sorafenib group had significantly decreased VEGF levels and a higher TNF‑α level than the other 2 groups (P<0.05). The adverse reaction rate was significantly lower than that of the surgery combined with cytokines group (P<0.05). In conclusion, sorafenib improves the early RCC postoperative survival rate and prolongs the survival time while reducing the recurrence rate. It does not increase adverse reactions, and improves renal function, by decreasing the level of VEGF, and improving the level of TNF‑α.

View Figures

View References

1	Flaherty KT: Sorafenib: Delivering a targeted drug to the right targets. Expert Rev Anticancer Ther. 7:617–626. 2007. View Article : Google Scholar : PubMed/NCBI
2	Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, et al: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 24:2505–2512. 2006. View Article : Google Scholar : PubMed/NCBI
3	Hampton T: Cancer drug trials show modest benefit: Drugs target liver, gastric, head and neck cancers. JAMA. 298:273–275. 2007. View Article : Google Scholar : PubMed/NCBI
4	Strumberg D: Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc). 41:773–784. 2005. View Article : Google Scholar : PubMed/NCBI
5	Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, et al: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 24:4293–4300. 2006. View Article : Google Scholar : PubMed/NCBI
6	Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140. 2008. View Article : Google Scholar : PubMed/NCBI
7	Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al: BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
8	Pagano M, Sierra NM, Panebianco M, Rossi G, Gnoni R, Bisagni G and Boni C: Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations. Anticancer Res. 34:5105–5110. 2014.PubMed/NCBI
9	Shi WH, Bian YH, Song XH and Wu JC: Co-administration of Sorafenib with adriamycin inhibits cell proliferation in hepatocellular carcinoma cells HepG2. Prog Mod Biomed. 24:4845–3848. 2011.
10	Kondo T, Nakazawa H, Oya M, Kimura G, Fujii Y, Hatano T, Kawata N, Kume H, Morita M, Nakajima K, et al: Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib. Jpn J Clin Oncol. 45:274–280. 2015. View Article : Google Scholar : PubMed/NCBI
11	Mori Y, Cai K, Cheng Y, Wang S, Paun B, Hamilton JP, Jin Z, Sato F, Berki AT, Kan T, et al: A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer. Gastroenterology. 131:797–808. 2006. View Article : Google Scholar : PubMed/NCBI
12	Zhao J, Zhu Y, Zhang C, Wang X, He H, Wang H, Wu Y, Zhou W and Shen Z: Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence. Urol Oncol. 31:1800–1805. 2013. View Article : Google Scholar : PubMed/NCBI
13	Wang ZY, Sun T and Ma M: The effects of G250-DC-CIK cells combined with sorafenib on renal tumor cell. Chin J Biochem Pharm. 32:225–228. 2011.
14	Gaudino M, Lau C, Cammertoni F, Vargiu V, Gambardella I, Massetti M and Girardi LN: Surgical treatment of renal cell carcinoma with cavoatrial involvement: A systematic review of the literature. Ann Thorac Surg. 101:1213–1221. 2016. View Article : Google Scholar : PubMed/NCBI
15	Antonelli A, Sodano M and Tardanico R: Response to editorial comment to features, risk factors and clinical outcome of ‘very late’ recurrences after surgery for localized renal carcinoma: a retrospective evaluation of a cohort with a minimum of 10 years of follow up. Int J Urol. 23:412016. View Article : Google Scholar : PubMed/NCBI
16	Randall JM, Millard F and Kurzrock R: Molecular aberrations, targeted therapy, and renal cell carcinoma: Current state-of-the-art. Cancer Metastasis Rev. 33:1109–1124. 2014. View Article : Google Scholar : PubMed/NCBI
17	Miyake H, Muramaki M, Imai S, Harada KI and Fujisawa M: Changes in renal function of patients with metastatic renal cell carcinoma during treatment with molecular-targeted agents. Target Oncol. 27:45–47. 2015.
18	Choi KH, Yu YD, Kang MH and Park DS: Sorafenib treatment for recurrent stage T1 bilateral renal cell carcinoma in patients with Von Hippel-Lindau disease: A case report and literature review. Can Urol Assoc J. 9:E651–E653. 2015. View Article : Google Scholar : PubMed/NCBI
19	Lin CH, Yuan HJ, Wang K, Wu JT, Liu QZ, Yu SQ, Men CP, Gao ZL and Wang J: Initial experience of sorafenib neoadjuvant therapy combined with retroperitoneoscopy in treating T2 large renal carcinoma. BioMed Res Int. 2015:6095492015. View Article : Google Scholar : PubMed/NCBI
20	Eriksen KW, Søndergaard H, Woetmann A, Krejsgaard T, Skak K, Geisler C, Wasik MA and Odum N: The combination of IL-21 and IFN-alpha boosts STAT3 activation, cytotoxicity and experimental tumor therapy. Mol Immunol. 46:812–820. 2009. View Article : Google Scholar : PubMed/NCBI